DEPLOYDatabase

Company

Synchron

Synchron is a brain-computer interface (BCI) company developing the Stentrode, a stentrode-based BCI implant that does not require open-brain surgery.

Founded
2016
HQ
New York, NY, USA
Status
private

The verified answer

As of Oct 2026, DEPLOY verifies Synchron: 1 model, 5 deployments across 3 regions, $200.0M raised. 1 source back the record.

CategoryWearable AI

Overview

Synchron is a brain-computer interface (BCI) company developing the Stentrode, a stentrode-based BCI implant that does not require open-brain surgery. Founded by neurologist Tom Oxley, the company has raised over $345M in total funding including a $200M Series D in 2024. Synchron's COMMAND and Switch clinical trials demonstrated no serious device-related adverse events across 6 patients, and the FDA has approved the Stentrode for early feasibility studies. The company is based in New York with origins in Melbourne, Australia.

Verified record

Verified deployments
5 deployments on file
Active incidents
None on file

Valuation of record

DEPLOY VERIFIED
$2.4B (reported, approximate)as of Dec 2024

Priced roundSeries D post-money

See the full valuations ranking →

Key facts

CEO

Tom Oxley (Founder, neurologist, Mount Sinai)

Product

Stentrode (endovascular BCI implant, no open-brain surgery)

Clinical trials

COMMAND (US, FDA-approved), SWITCH (Australia, 4 patients)

Safety

No serious device-related adverse events in 6 patients

Target

Patients with severe paralysis (ALS) to communicate via thought

Data & sources

Web sources

1

1 source backing this record.View all →

Relationships

Current leadership (1)

  • Tom Oxley Founder & CEOreported, not verified

Founders (1)

See all founders across the registry →

Safety record

No incidents on record for Synchron.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Operator customers (1)

Recent coverage

Synchron in third-party press

Peers

3 peers across 1 segment. Every Synchron competitor derived from shared form-factor and application-domain edges.

bci(3)

3 companies in this segment · highly_concentrated (HHI 3365.5523463639224) · leader Blackrock Neurotech at 3565%